

## **AGENDA**

**Uniform Formulary Beneficiary Advisory Panel (BAP)  
27 September 2018 @ 9:00 AM**

**Naval Heritage Center Theater  
701 Pennsylvania Ave., N.W., Washington, DC 20004**

- **Administrative Meeting (BAP members report no later than 7:30 AM)**
- **Sign-In**
- **Welcome and Opening Remarks**
- **Public Citizen Comments**
- **Therapeutic Class Reviews**

*Members of the DHA Pharmacy Operations Division (POD) Formulary Management Branch (FMB) will present relative clinical and cost-effective analyses along with the DoD Pharmacy & Therapeutics Committee (P&T) recommendations for the Uniform Formulary (UF).*

*The P&T Committee made recommendations for the following drugs/drug classes during the August 2018 meeting:*

- **Drug Class Reviews**
  - *Corticosteroids-Immune Modulators: Atopic Dermatitis Subclass*
  - *Hepatitis C Virus (HCV) Direct-Acting Antivirals (DAAs) Subclass*
  - *Corticosteroids-Immune Modulators: Adrenocorticotrophic Hormones (ACTH)*
- **Newly Approved Drugs per 32 CFR 199.21(g)(5)**
  - *abiraterone acetate micronized (Yonsa) – Oral Oncologic Agent for Prostate Cancer*
  - *amantadine extended release tablets (Osmolex ER) – Parkinson’s Agent*
  - *avatrombopag (Doptelet) – Hematological Agent: Platelets for Thrombocytopenia in Chronic Liver Disease*
  - *baricitinib (Olumiant) – Targeted Immunomodulatory Biologic (TIB) for Rheumatoid Arthritis*
  - *binimetinib (Mektovi) – Oral Oncologic Agent for Metastatic Melanoma*
  - *encorafenib (Braftovi) – Oral Oncologic Agent for Metastatic Melanoma*
  - *epoetin-alfa-epbx (Retacrit) injection – Hematological Agent: Red Blood Cell Stimulant for Erythropoiesis*
  - *erenumab-aooe (Aimovig) injection– Migraine Agent (calcitonin gene-related peptide [CGRP]) for Migraine Headache Prophylaxis*

- *estradiol (Imvexxy) vaginal insert – Miscellaneous Gynecological Agent for Dyspareunia*
- *fostamatinib (Tavalisse) – Hematological Agent: Platelets for Chronic Immune Thrombocytopenia*
- *hydroxyurea (Siklos) tablets – Hematological Agent: Sickle Cell Anemia Agent for Sickle Cell Anemia in Pediatrics*
- *levonorgestrel/ethinyl estradiol/ferrous (Balcoltra) – Oral Combined Contraceptive Agent*
- *lofexidine (Lucemyra) – Alpha 2 Antagonist for Mitigation of Symptoms of Opioid Withdrawal*
- *oxycodone IR (Roxybond) – Narcotic Analgesic Abuse Deterrent Formulation for Pain*
- *pegvaliase-pqpz (Palynziq) injection – Miscellaneous Metabolic Agent for Phenylketonuria*
- *tolvaptan (Jynarque) – Miscellaneous Nephrology Agent for Rapidly Progressing Autosomal Dominant Polycystic Kidney Disease (ADPKD)*

➤ **Utilization Management Issues**

- *Prior Authorization Criteria—Updated Criteria*
  - *Epinephrine Auto-Injectors: Auvi-Q Temporary Removal of Manual PA*
  - *Renin Angiotensin Antihypertensive Agents (RAAs): candesartan and candesartan/HCTZ Step Therapy*
  - *Oncological Agents for unresectable or metastatic melanoma: Dabrafenib (Tafinlar), Trametinib (Mekinist), and vemurafenib (Zelboraf)*
  - *Oncological Agents: Prostate II - enzalutamide (Xtandi)*
  - *TIBs: Tofacitinib (Xeljanz/Xeljanz XR)*

➤ **Panel Discussions**

*The UF BAP will have the opportunity to ask questions to each of the presenters. Upon completion of the presentation and any questions, the Panel will discuss the recommendations and vote to accept or reject them. The Panel will provide comments on their vote as directed by the Panel Chairman.*